Skip to main content

Advertisement

SpringerLink
Log in

Advanced breast cancer: anti-progressive immunotherapy using a thermostable autologous hemoderivative

  • Clinical Trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Introduction

Advanced breast cancer patients, acquired-chemotherapy resistant and in progression, are therapeutically terminal. We tested a recently described medical procedure using a thermostable autohemoderivative purported to inhibit tumor growth possibly through an immunological mechanism of action.

Patients and methods

Metastatic breast cancer patients, chemotherapy-resistant, high CEA and CA 15-3 plasma levels of tumor markers, in progression, were 2-group randomized. Group 1 received the test procedure and Group 2 adequate measures to be comparable control. From 121 included patients, 108 could be evaluated. During 8-month follow-up period, tumor growth, number of cases attaining clinical non-progressive status and mortality were monthly assessed. Immunologic effect was assessed by delayed type hypersensitivity test and lymphocyte proliferation assay. Responding-tumors histopathologies were studied. The proteome of the autologous immunogen was characterized by 2-D electrophoresis.

Results and discussion

In a significant number of cases, the test procedure promoted inhibition of tumor growth, non-progressive disease status, and lower cumulative mortality. These clinical results were associated with polyvalent immunization against several tested antigens: the hemoderivative used for treatment, the blood tumor markers and the derivative obtained from a regulatory lymphocyte population (CD4+CD25+). Interference with this regulatory activity could explain the selective autoimmunity suggested by the histopathology findings in responding tumors. The thermostability could be an essential property of the immunogen hemoderivative.

Conclusion

The thermostable autohemoderivative tested is antigenically polyvalent and promoted a polytargeted immune response associated to a tumor anti-progressive effect, consequently, acting as an autohemoderivative cancer vaccine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lasalvia E, Cucchi S, DeStefani E et al (1995) Autologous induction of tumoral fibrogenesis. Neoplasia 12(1):5–10

    Google Scholar 

  2. Lasalvia E, Cucchi S, Carlevaro T et al (1995) Anti-metastatic␣effect of a blood fraction from cancer patients. (Meeting abstract). Proceedings 31st Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, USA, Abstract No: 730

  3. Lasalvia-Prisco E, Cucchi S, Vázquez J et al (2003) Antitumoral effect of a vaccination procedure with an autologous hemoderivative. Cancer Biol Ther March/April 2(2):155–160

    Google Scholar 

  4. Berd D, Mastrangelo MJ, Engstrong P et al (1982) Augmentation of the human immune response by cyclophosphamide. Cancer Res 42:4862–4866

    PubMed  CAS  Google Scholar 

  5. Leong SP, Enders-Zohr P, Zhou YM et al (1999) Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother 22(2):166–174

    Article  PubMed  CAS  Google Scholar 

  6. Lasalvia-Prisco E, Garcia-Giralt E, Cucchi S et al (2006) Advanced colon cancer: antiprogressive immunotherapy using an autologous hemoderivative. Med Oncol 23(1):91–104

    Google Scholar 

  7. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655

    PubMed  CAS  Google Scholar 

  8. Therasse P, Arbuck SG, Einsenhauer EA et al (2000) New guideline to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  9. World Medical Association Declaration of Helsinki: Recommendations guiding medical doctors in biomedical research involving human subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964 and as revised in Tokyo, 1975, in Venice, 1983, in Hong Kong, 1989. Version with changes of 1997

  10. PDQ (Physician Data Query) National Cancer Institute, comprehensive cancer database

  11. Garcia-Giralt E, Lasalvia-Prisco E, Cucchi S et al (2005) Breast cancer: role of tumor associated antigens and regulatory cells [CD4+CD25+] as targets of the immune response elicited by an anti-progressive autologous hemoderivative vaccine (Meeting abstract). Proceedings 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, USA, Abstract No. 2589

  12. Wan Fai Ng, Dugan Phillip J, Ponchel FE et al (2001). Human CD4+CD25+ cells: a naturally occurring population of regulatory T cells. Blood 98(9):2736–2744

    Article  Google Scholar 

  13. Gauthier LR, Granotier C, Soria JC et al (2001) Detection of circulating carcinoma cells by telomerase activity. Br J Cancer 84(5):631–635

    Article  PubMed  CAS  Google Scholar 

  14. Langen H, Roeder D, Juranville JF et al (1997) Effect of the protein application mode and the acrylamide concentration on the resolution of protein spots separated by two-dimensional gel electrophoresis. Electrophoresis 18:2085–2090

    Article  PubMed  CAS  Google Scholar 

  15. National Cancer Institute, US: Common terminology criteria for adverse events v3.0 (CTCAE)

  16. Fountoulakis M, Juranville JF, Jiang L et al (2004) Depletion of the high-abundance plasma proteins. Amino Acids 27:249–259

    Article  PubMed  CAS  Google Scholar 

  17. Jones E, Dahm-Vicker M, Simon AK et al (2002) Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun. 2:1–12

    PubMed  Google Scholar 

  18. Liyanage UK, Moore TT, Hong-Gu Joo et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756–2761

    PubMed  CAS  Google Scholar 

  19. Josic D, Buchacher A, Kannicht C et al (1999) Degradation products of factor VIII which can lead to increased immunogenicity. Vox Sang 77:90–99

    Google Scholar 

  20. Robinson WE Jr, Montefiori DC, Mitchell WM (1988) Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1:790–794

    Google Scholar 

  21. Abeyounis CJ, Milgrom F (1976) A thermostable antigen characteristic for carcinogen-induced rat intestinal tumors. J␣Immunol 116(1):30–34

    PubMed  CAS  Google Scholar 

  22. Lomakin MS, Larin AS, Maiskii IN (1978) Thermostable antigens of malignant tumors and normal tissues of experimental animals [Termostabil’nye antigeny zlokachestvennykh tkanei eksperimental’nykh zhivotnykh]. Biull Eksp Biol Med 85(6):726–728

    Article  PubMed  CAS  Google Scholar 

  23. Lomakin MS, Larin AS, Maiskii IN (1980) Thermo-stable tumor-associated antigens in the serum of tumor-bearing animals and in tissue cultures of malignant tumors [Termostabil’nye opukhole-assotsiirovannye antigeny v syvorotke krovi zhivotnykh-opukholenositelei i v kul’ture tkani zlokachestvennykh opukholei]. Biull Eksp Biol Med 89(4):452–454

    Article  PubMed  CAS  Google Scholar 

  24. Hampton R, Walker M, Marshall J et al (2002). Differential expression of carcinoembryonic antigen (CEA) splice variants in whole blood of colon cancer patients and healthy volunteers: implication for the detection of circulating colon cancer cells. Oncogene 21(51):7817–7823

    Article  PubMed  CAS  Google Scholar 

  25. Burton RM, Hope NJ, Lubbers (1976) A thermostable antigen associated with ovarian cancer. Am J Obstet Gynecol 125(4):472–477

    PubMed  CAS  Google Scholar 

  26. Conry RM, Khazaeli MB, Saleh MN et al (1999) Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res 5(9):2330–2337

    PubMed  CAS  Google Scholar 

  27. Saetang T, Suttijitpaisal P, Ratanabanangkoon K (1998). Preparations of toxic components from Naja kaouthia venom by selective heat denaturation. J Nat Toxins 7(1):37–44

    PubMed  CAS  Google Scholar 

  28. Petrunin DD, Lopukin Iu M, Molodenkov MN et al (1982). Immunochemical identification of thermostable alpha-glycoprotein in blood sera in various immune system diseases. Biull Eksp Biol Med 93(4):66–68

    Article  PubMed  CAS  Google Scholar 

  29. Bruster HTH, Kuntz BME, Scheja JW (1988) Autovaccination plus heat-inactivated autologous plasma in AIDS patients. Lancet 4:1284–1285

    Article  Google Scholar 

  30. Snegotska O (1965) Autovaccines for the treatment of cancer. Folia Clin Int (Barc Spain) 5(6):303–308

    Google Scholar 

  31. Karcher D, Lowenthal A, Stoppie P et al (1984) A serum protein affecting the regulation of the immune system. Neurochem Res 9(10): 1423–1430

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. PharmaBlood Inc, Research & Development Department, 2050 NE 163rd Street, # 202, North Miami Beach, Florida, 33162, USA

    Eduardo Lasalvia-Prisco

  2. National Institute of Oncology, 8 de Octubre s/n, Montevideo, Uruguay (Initial Data)

    Jesús Vázquez, Wilson Golomar & Joshemaria Larrañaga

  3. Centre De Cancerologie Hartmann, 26, Boulevard Victor-Hugo, 92200, Neuilly Sur Seine, France

    Emilio Garcia-Giralt

  4. Interdoctors, Department of Advanced Medical Treatments, 8 de Octubre 2323, # 905, Montevideo, Uruguay

    Jesús Vázquez, Wilson Golomar, Joshemaria Larrañaga, Silvia Cucchi & Eduardo Lasalvia-Galante

Authors
  1. Eduardo Lasalvia-Prisco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jesús Vázquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wilson Golomar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joshemaria Larrañaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Emilio Garcia-Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Silvia Cucchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eduardo Lasalvia-Galante
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eduardo Lasalvia-Prisco.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lasalvia-Prisco, E., Vázquez, J., Golomar, W. et al. Advanced breast cancer: anti-progressive immunotherapy using a thermostable autologous hemoderivative. Breast Cancer Res Treat 100, 149–160 (2006). https://doi.org/10.1007/s10549-006-9235-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-006-9235-7

Keywords

Search

Navigation